Synthesis and structure-activity relationships of C-glycosylated oxadiazoles as inhibitors of glycogen phosphorylase.

A series of per-O-benzoylated 5-beta-D-glucopyranosyl-2-substituted-1,3,4-oxadiazoles was prepared by acylation of the corresponding 5-(beta-D-glucopyranosyl)tetrazole. As an alternative, oxidation of 2,6-anhydro-aldose benzoylhydrazones by iodobenzene I,I-diacetate afforded the same oxadiazoles. 1,3-Dipolar cycloaddition of nitrile oxides to per-O-benzoylated beta-D-glucopyranosyl cyanide gave the corresponding 5-beta-D-glucopyranosyl-3-substituted-1,2,4-oxadiazoles. The O-benzoyl protecting groups were removed by base-catalyzed transesterification. The 1,3,4-oxadiazoles were practically inefficient as inhibitors of rabbit muscle glycogen phosphorylase b while the 1,2,4-oxadiazoles displayed inhibitory activities in the micromolar range. The best inhibitors were the 5-beta-D-glucopyranosyl-3-(4-methylphenyl- and -2-naphthyl)-1,2,4-oxadiazoles (K(i)=8.8 and 11.6 microM, respectively). A detailed analysis of the structure-activity relationships is presented.

[1]  S. Zographos,et al.  New inhibitors of glycogen phosphorylase as potential antidiabetic agents. , 2008, Current medicinal chemistry.

[2]  Zhenhua Shang.  Oxidative Cyclization of Aromatic Aldehyde N‐Acylhydrazones by bis(Trifluoroacetoxy)iodobenzene , 2006 .

[3]  L. Somsák,et al.  Preparation of C-(2-deoxyhex/pent-1-enopyranosyl)heterocycles. , 1994, Carbohydrate research.

[4]  Paul Zimmet,et al.  Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. , 2004, Diabetes care.

[5]  A. Scilimati,et al.  Stereoselective dimerization of 3-arylisoxazoles to cage-shaped bis-β-lactams syn 2,6-diaryl-3,7-diazatricyclo[4.2.0.02,5]octan-4,8-diones induced by hindered lithium amides , 2007 .

[6]  T. Barrett,et al.  The emergence of type 2 diabetes in childhood , 2004, Annals of clinical biochemistry.

[7]  J. Treadway,et al.  Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus , 2001, Expert opinion on investigational drugs.

[8]  K. C. Chandra Sekhar,et al.  Iodobenzene Diacetate Mediated Solid‐State Synthesis of Heterocyclyl‐1,3,4‐oxadiazoles , 2004 .

[9]  J. Gardiner,et al.  Preparation of modified nucleosides from glucosamine: rapid and efficient formal total synthesis of several 2′-deoxy C-nucleosides , 1990 .

[10]  Zheng Li,et al.  Microwave‐Assisted Expeditious Synthesis of Novel Carbazole‐Based 1,3,4‐Oxadiazoles , 2006 .

[11]  J. Praly,et al.  In Search of Glycogen Phosphorylase Inhibitors: 5-Substituted 3-C-Glucopyranosyl-1,2,4-oxadiazoles from β-D-Glucopyranosyl Cyanides upon Cyclization of O-Acylamidoxime Intermediates , 2006 .

[12]  Z. Bloomgarden,et al.  Type 2 diabetes in the young: the evolving epidemic. , 2004, Diabetes care.

[13]  L. Somsák,et al.  Synthesis of N-(β-D-glucopyranosyl)- and N-(2-acetamido-2-deoxy-β-D-glucopyranosyl) amides as inhibitors of glycogen phosphorylase , 2004 .

[14]  E. Krebs,et al.  [49a] Muscle phosphorylase b: x Glucose-1-phosphate+ Gn ⇄ Gn+x + x inorganic phosphate(where Gn designates glycogen containing n glucose residues) , 1962 .

[15]  R. Wightman,et al.  Synthesis of C-glycosyltetrazoles related to 3-deoxy-D-arabino-heptulosonic acid 7-phosphate (DAHP); potential inhibitors of early steps in the shikimate pathway , 1992 .

[16]  D. Moller,et al.  New drug targets for type 2 diabetes and the metabolic syndrome , 2001, Nature.

[17]  M. Dabiri,et al.  A facile procedure for the one-pot synthesis of unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles , 2006 .

[18]  B. V. Ashalatha,et al.  Synthesis of some new biologically active 1,3,4-oxadiazolyl nitroindoles and a modified Fischer indole synthesis of ethyl nitro indole-2-carboxylates. , 2005, Bioorganic & medicinal chemistry.

[19]  J. Praly,et al.  1,3-Dipolar cycloaddition reactions on carbohydrate-based templates: synthesis of spiro-isoxazolines and 1,2,4-oxadiazoles as glycogen phosphorylase inhibitors , 2006 .

[20]  L. Somsák,et al.  C-(β-D-glucopyranosyl) heterocycles as potential glycogen phosphorylase inhibitors , 2004 .

[21]  L. Szilágyi,et al.  Preparation of 3,5-bis-(β-D-glycopyranosyl)-1,2,4-thiadiazoles from C-(β-D-glycopyranosyl)thioformamides , 2001 .

[22]  F. McAlister,et al.  A systematic review of drug therapy to delay or prevent type 2 diabetes. , 2005, Diabetes care.

[23]  N. Oikonomakos.  Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. , 2002, Current protein & peptide science.

[24]  N. Oikonomakos,et al.  Kinetic and crystallographic studies on 2‐(β‐D‐glucopyranosyl)‐5‐methyl‐1, 3, 4‐oxadiazole, ‐benzothiazole, and ‐benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site , 2005, Protein science : a publication of the Protein Society.

[25]  L. Agius.  New hepatic targets for glycaemic control in diabetes. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[26]  B. Tóth,et al.  Efficient inhibition of muscle and liver glycogen phosphorylases by a new glucopyranosylidene-spiro-thiohydantoin. , 1999, Bioorganic & medicinal chemistry letters.

[27]  B. Tóth,et al.  Synthesis of and a comparative study on the inhibition of muscle and liver glycogen phosphorylases by epimeric pairs of d-gluco- and d-xylopyranosylidene-spiro-(thio)hydantoins and N-(d-glucopyranosyl) amides. , 2001, Journal of medicinal chemistry.

[28]  R. Perfetti,et al.  Novel strategies for the pharmacological management of type 2 diabetes. , 2004, Trends in pharmacological sciences.

[29]  Richard M Hoffman,et al.  Hypoglycemia in type 2 diabetes: a critical review. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  B. Tóth,et al.  Binding of N-acetyl-N '-beta-D-glucopyranosyl urea and N-benzoyl-N '-beta-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies. , 2002, European journal of biochemistry.

[31]  N. Oikonomakos,et al.  In the search of glycogen phosphorylase inhibitors : Synthesis of C-D-glycopyranosylbenzo (hydro )quinones-inhibition of and binding to glycogen phosphorylase in the crystal , 2007 .

[32]  I. Farkas,et al.  Conversion of acetylated glycosyl cyanides into C-glycosyl derivatives of benzothiazole and tetrazole , 1977 .

[33]  László Szilágyi,et al.  Kinetic and crystallographic studies of glucopyranosylidene spirothiohydantoin binding to glycogen phosphorylase B. , 2002, Bioorganic & medicinal chemistry.

[34]  L. Johnson,et al.  Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection. , 1995, Acta crystallographica. Section D, Biological crystallography.

[35]  M. Makishima,et al.  Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist. , 2007, Bioorganic & medicinal chemistry.

[36]  I. G. Fantus,et al.  Oral antihyperglycemic therapy for type 2 diabetes mellitus , 2005, Canadian Medical Association Journal.

[37]  L. Somsák,et al.  Preparation of 2,6-anhydro-aldose acylhydrazones, -semicarbazones and -oximes from 2,6-anhydro-aldononitriles (glycosyl cyanides). , 2003, Carbohydrate research.

[38]  N. Morral,et al.  Novel targets and therapeutic strategies for type 2 diabetes , 2003, Trends in Endocrinology & Metabolism.

[39]  C. van Weel,et al.  Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. , 2005, Diabetes care.

[40]  J. Nuss,et al.  Current therapies and emerging targets for the treatment of diabetes. , 2001, Current pharmaceutical design.

[41]  G. Kumaran,et al.  SYNTHESIS OF ALPHA -FUNCTIONALIZED AND NONFUNCTIONALIZED HYDROXIMOYL CHLORIDES FROM CONJUGATED NITROALKENES AND NITROALKANES , 1997 .